$4.28
+0.01 (+0.23%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IMDX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 observational
Held by 4 tracked-famous managers (JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 11.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) TrialNCT07551531observationalDetect Rejection | — | Not yet recruiting | — | Kidney Transplant | 5,000 | Dec 2032 | ≤ 2,326 d | 2026-07-30 |
| Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant MonitoringNCT07060716observationalClinical validation of the dd-cfDNA test when compared to biopsy-confirmed rejection | — | Recruiting | Diagnostic test: donor-derived cell-free DNA test | Kidney Transplant Rejection, Cell-free DNA | 125 | 2025-11-30 | — | 2025-11-19 |
| Predictive Assay for Decision Making in Adjuvant TherapyNCT05032352observationalFree Survival (DFS) | — | Terminatedsponsor's stated reason: Non-safety related, reallocation of resources | Drug: Adjuvant · Other: Observation | Carcinoma, Non-Small-Cell Lung | 55 | 2022-10-28actual | — | 2022-11-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19